These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 35252767)

  • 1. Psychosocial Stress, Glucocorticoid Signaling, and Prostate Cancer Health Disparities in African American Men.
    Woods-Burnham L; Stiel L; Martinez SR; Sanchez-Hernandez ES; Ruckle HC; Almaguel FG; Stern MC; Roberts LR; Williams DR; Montgomery S; Casiano CA
    Cancer Health Disparities; 2020; 4():. PubMed ID: 35252767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoids Induce Stress Oncoproteins Associated with Therapy-Resistance in African American and European American Prostate Cancer Cells.
    Woods-Burnham L; Cajigas-Du Ross CK; Love A; Basu A; Sanchez-Hernandez ES; Martinez SR; Ortiz-Hernández GL; Stiel L; Durán AM; Wilson C; Montgomery S; Roy S; Casiano CA
    Sci Rep; 2018 Oct; 8(1):15063. PubMed ID: 30305646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor suppressive miR-99b-5p as an epigenomic regulator mediating mTOR/AR/SMARCD1 signaling axis in aggressive prostate cancer.
    Waseem M; Gujrati H; Wang BD
    Front Oncol; 2023; 13():1184186. PubMed ID: 38023145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor-target genes in african american prostate cancer disparities.
    Wang BD; Yang Q; Ceniccola K; Bianco F; Andrawis R; Jarrett T; Frazier H; Patierno SR; Lee NH
    Prostate Cancer; 2013; 2013():763569. PubMed ID: 23365759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of glucocorticoid receptor in castration resistant prostate cancer: A potential therapeutic target.
    Kumar R
    J Cancer; 2020; 11(3):696-701. PubMed ID: 31942193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.
    Berchuck JE; Adib E; Abou Alaiwi S; Dash AK; Shin JN; Lowder D; McColl C; Castro P; Carelli R; Benedetti E; Deng J; Robertson M; Baca SC; Bell C; McClure HM; El Zarif T; Davidsohn MP; Lakshminarayanan G; Rizwan K; Skapura DG; Grimm SL; Davis CM; Ehli EA; Kelleher KM; Seo JH; Mitsiades N; Coarfa C; Pomerantz MM; Loda M; Ittmann M; Freedman ML; Kaochar S
    Cancer Res; 2022 Aug; 82(16):2848-2859. PubMed ID: 35731919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.
    Mahal BA; Gerke T; Awasthi S; Soule HR; Simons JW; Miyahira A; Halabi S; George D; Platz EA; Mucci L; Yamoah K
    Eur Urol Oncol; 2022 Feb; 5(1):18-29. PubMed ID: 34446369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
    Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms involving prostate cancer racial disparity.
    Karakas C; Wang C; Deng F; Huang H; Wang D; Lee P
    Am J Clin Exp Urol; 2017; 5(3):34-48. PubMed ID: 29181436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
    Kach J; Long TM; Selman P; Tonsing-Carter EY; Bacalao MA; Lastra RR; de Wet L; Comiskey S; Gillard M; VanOpstall C; West DC; Chan WC; Griend DV; Conzen SD; Szmulewitz RZ
    Mol Cancer Ther; 2017 Aug; 16(8):1680-1692. PubMed ID: 28428441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer racial, socioeconomic, geographic disparities: targeting the genomic landscape and splicing events in search for diagnostic, prognostic and therapeutic targets.
    Marima R; Hull R; Mathabe K; Setlai B; Batra J; Sartor O; Mehrotra R; Dlamini Z
    Am J Cancer Res; 2021; 11(4):1012-1030. PubMed ID: 33948343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
    Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
    Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress.
    Lee JH; Kang M; Wang H; Naik G; Mobley JA; Sonpavde G; Garvey WT; Darley-Usmar VM; Ponnazhagan S
    FASEB J; 2017 Apr; 31(4):1608-1619. PubMed ID: 28069826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.